Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Dec;16(6):722-731.
doi: 10.18502/ijm.v16i6.17244.

Systematic review and meta-analysis of colistin plus meropenem therapy for the treatment of nosocomial pneumonia

Affiliations
Review

Systematic review and meta-analysis of colistin plus meropenem therapy for the treatment of nosocomial pneumonia

Hazhir Moradi et al. Iran J Microbiol. 2024 Dec.

Abstract

Background and objectives: Nosocomial pneumonia caused by multidrug-resistant gram-negative bacteria presents a significant challenge for healthcare systems, as there are limited effective treatments available. This systematic review and meta-analysis aim to investigate the outcomes of colistin plus meropenem combination therapy on nosocomial pneumonia.

Materials and methods: An exhaustive search of PubMed, Scopus, Web of Science (WOS), and Embase databases was conducted, resulting in the extraction of 5 studies for qualitative assessment and meta-analysis. The study sample included 991 patients admitted with nosocomial pneumonia. The outcomes evaluated were clinical improvement, microbiological response, mortality, Sequential Organ Failure Assessment (SOFA) score, Acute Physiology and Chronic Health Evaluation (APACHE II) score, Charlson Comorbidity Index (CCI), Clinical Pulmonary Infection Score (CPIS), C-reactive protein (CRP) levels, procalcitonin (PCT) levels, and intensive care unit (ICU) duration.

Results: The results demonstrated that colistin plus meropenem combination therapy significantly improved clinical outcomes (OR = 1.37, 95% CI = 1.04-1.81, p = 0.027), reduced SOFA scores (OR = -0.28, 95% CI = -0.44 to -0.11, p = 0.001), and increased CCI scores (OR = 0.16, 95% CI = 0.02-0.29, p = 0.021) compared to other medications. However, other evaluated parameters did not show significant differences.

Conclusion: This meta-analysis indicates that colistin-meropenem combination therapy is superior to other colistin-based treatments for nosocomial pneumonia in terms of clinical improvement, SOFA score reduction, and CCI score increase. Nevertheless, other variables assessed did not exhibit remarkable differences between the treatment regimens.

Keywords: Colistin; Meropenem; Multiple drug-resistance; Nosocomial infection; Pneumonia.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Flow chart illustrating summary of literature search results
Fig. 2.
Fig. 2.
The forest plot and point estimate of outcomes
Fig. 3.
Fig. 3.
Funnel plot analysis on the detection of publication bias in the meta-analysis. (owing to the limited number of studies on the CPIS scores outcome (fewer than three studies), the procedures for detecting publication bias were not executed. Consequently, the funnel plot for this outcome in not available.)

Similar articles

References

    1. Tesini BL, Dumyati G. Health care-associated infections in older adults: epidemiology and prevention. Infect Dis Clin North Am 2023; 37: 65–86. - PubMed
    1. Zilberberg MD, Shorr AF, Micek ST, Vazquez-Guillamet C, Kollef MH. Multi-drug resistance, inappropriate initial antibiotic therapy and mortality in Gram-negative severe sepsis and septic shock: a retrospective cohort study. Crit Care 2014; 18: 596. - PMC - PubMed
    1. Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 2016; 63(5): e61–e111. - PMC - PubMed
    1. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18: 268–281. - PubMed
    1. Cheng I-L, Chen Y-H, Lai C-C, Tang H-J. Intravenous colistin monotherapy versus combination therapy against carbapenem-resistant gram-negative bacteria infections: meta-analysis of randomized controlled trials. J Clin Med 2018; 7: 208. - PMC - PubMed

LinkOut - more resources